X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.980
-0.020 (-0.50%)
At close: Jul 31, 2026, 4:00 PM EDT
3.970
-0.010 (-0.25%)
After-hours: Jul 31, 2026, 7:34 PM EDT
X4 Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 216.91 | 217.05 | 55.7 | 99.22 | 121.72 | 81.79 |
Short-Term Investments | 16.81 | 35.95 | 46.36 | 15 | - | - |
Cash & Short-Term Investments | 233.72 | 253 | 102.06 | 114.22 | 121.72 | 81.79 |
Cash Growth | 168.80% | 147.89% | -10.64% | -6.16% | 48.82% | 3.91% |
Accounts Receivable | 1.11 | 0.57 | 1.07 | - | - | - |
Other Receivables | - | - | 0.64 | 0.56 | 1.15 | 0.75 |
Total Trade Receivables | 1.11 | 0.57 | 1.71 | 0.56 | 1.15 | 0.75 |
Inventory | 4.64 | 4.48 | 2.82 | - | - | - |
Other Current Assets | 2.51 | 3.53 | 5.59 | 7.3 | 5.81 | 5.34 |
Total Current Assets | 241.98 | 261.58 | 112.18 | 122.08 | 128.68 | 87.88 |
Net Property, Plant & Equipment | 1.18 | 1.59 | 4.84 | 6.4 | 8.33 | 10.22 |
Other Intangible Assets | 9.06 | 9.25 | 10 | - | - | - |
Goodwill | 17.35 | 17.35 | 17.35 | 17.35 | 17.35 | 17.35 |
Other Long-Term Assets | 0.7 | 0.69 | 2.08 | 1.44 | 1.23 | 1.72 |
Total Assets | 270.28 | 290.46 | 146.45 | 147.26 | 155.59 | 117.18 |
Accounts Payable | 5.07 | 5.7 | 8.62 | 8.95 | 7.78 | 4.28 |
Accrued Expenses | 17.06 | 18.6 | 23.01 | 12.82 | 12.03 | 7.87 |
Current Portion of Long-Term Debt | - | - | - | - | 1.32 | 0.8 |
Current Portion of Leases | 0.73 | 0.99 | 1.25 | 1.1 | 1.2 | 1.08 |
Unearned Revenue | 0.91 | 0.46 | - | - | - | - |
Total Current Liabilities | 23.77 | 25.76 | 32.88 | 22.86 | 22.32 | 14.02 |
Long-Term Debt | 76.52 | 76.29 | 75.43 | 54.57 | 32.3 | 33.14 |
Long-Term Leases | - | - | 1.41 | 2.61 | 3.6 | 4.78 |
Other Long-Term Liabilities | 1.54 | 2.12 | 14.59 | 16.12 | 23.3 | 0.83 |
Total Long-Term Liabilities | 78.06 | 78.41 | 91.42 | 73.3 | 59.21 | 38.74 |
Total Liabilities | 101.83 | 104.17 | 124.3 | 96.16 | 81.54 | 52.76 |
Common Stock | 0.09 | 0.09 | 0.01 | 0.17 | 0 | 0.03 |
Additional Paid-in Capital | 783.27 | 780.86 | 537.62 | 528.96 | 450.79 | 347.37 |
Accumulated Other Comprehensive Income | -0.12 | -0.11 | -0.12 | -0.12 | -0.12 | -0.12 |
Retained Earnings | -614.8 | -594.55 | -515.36 | -477.91 | -376.74 | -282.87 |
Shareholders' Equity | 168.45 | 186.29 | 22.15 | 51.1 | 73.93 | 64.41 |
Total Liabilities & Equity | 270.28 | 290.46 | 146.45 | 147.26 | 155.59 | 117.18 |
Total Debt | 77.25 | 77.29 | 78.09 | 58.28 | 38.42 | 39.79 |
Net Cash (Debt) | 156.47 | 175.71 | 23.97 | 55.94 | 83.3 | 42 |
Net Cash Growth | 1656.08% | 632.93% | -57.14% | -32.85% | 98.32% | 4.33% |
Net Cash Per Share | 2.17 | 4.16 | 3.58 | 9.44 | 39.34 | 48.94 |
Book Value | 168.45 | 186.29 | 22.15 | 51.1 | 73.93 | 64.41 |
Book Value Per Share | 2.34 | 4.40 | 3.30 | 8.62 | 34.91 | 75.05 |
Tangible Book Value | 142.04 | 159.69 | -5.2 | 33.75 | 56.58 | 47.06 |
Tangible Book Value Per Share | 1.97 | 3.78 | -0.78 | 5.69 | 26.72 | 54.83 |